{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T02:38:40Z","timestamp":1783996720527,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ijantimicag.2020.106210","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T12:36:40Z","timestamp":1603456600000},"page":"106210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5967-5211","authenticated-orcid":false,"given":"Michael P.","family":"Veve","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0921-549X","authenticated-orcid":false,"given":"Nimish","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1856-3357","authenticated-orcid":false,"given":"Samantha D.","family":"Yeager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6536-0558","authenticated-orcid":false,"given":"Laurence R.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3371-5101","authenticated-orcid":false,"given":"Mahmoud A.","family":"Shorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.106210_bib0001","unstructured":"DALVANCE (dalbavancin) package insert. Accessed 15 Jan 2020. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/021883s003lbl.pdf"},{"key":"10.1016\/j.ijantimicag.2020.106210_bib0002","unstructured":"XYDALBA (dalbavancin) package insert. Accessed 10 Mar 2020. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/xydalba-epar-summary-public_en.pdf."},{"issue":"5","key":"10.1016\/j.ijantimicag.2020.106210_bib0003","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ijantimicag.2019.08.006","article-title":"French national cohort of first use of dalbavancin: A high proportion of off-label use","volume":"54","author":"Dinh","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"10.1016\/j.ijantimicag.2020.106210_bib0004","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1093\/jac\/dkz162","article-title":"On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections","volume":"74","author":"Morrisette","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.ijantimicag.2020.106210_bib0005","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-duration dosing and distribution of dalbavancin into bone and articular tissue","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.ijantimicag.2020.106210_bib0006","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1128\/AAC.48.3.940-945.2004","article-title":"Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers","volume":"48","author":"Leighton","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106210_bib0007","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ijid.2019.02.013","article-title":"Multicenter clinical experience of real life Dalbavancin use in gram-positive infections","volume":"81","author":"Wunsch","year":"2019","journal-title":"Int J Infect Dis"},{"issue":"5","key":"10.1016\/j.ijantimicag.2020.106210_bib0008","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02280-18","article-title":"Safety and efficacy of prolonged use of dalbavancin in bone and joint infections","volume":"63","author":"Morata","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.ijantimicag.2020.106210_bib0009","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12941-019-0329-6","article-title":"DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and\/or bloodstream infection produced by gram-positive cocci","volume":"18","author":"Hidalgo-Tenorio","year":"2019","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"1","key":"10.1016\/j.ijantimicag.2020.106210_bib0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/cid\/cix733","article-title":"Rates of and risk factors for adverse drug events in outpatient parenteral antimicrobial therapy","volume":"66","author":"Keller","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.ijantimicag.2020.106210_bib0011","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciy745","article-title":"2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy","volume":"68","author":"Norris","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.ijantimicag.2020.106210_bib0012","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/jac\/dkt512","article-title":"Adverse events, healthcare interventions and healthcare utilization during home infusion therapy with daptomycin and vancomycin: a propensity score-matched cohort study","volume":"69","author":"Shrestha","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106210_bib0013","first-page":"459","article-title":"Managing an outpatient parenteral antibiotic therapy team: challenges and solutions","volume":"10","author":"Halilovic","year":"2014","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"10.1016\/j.ijantimicag.2020.106210_bib0014","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40121-019-0247-0","article-title":"Dalbavancin use in vulnerable patients receiving outpatient parenteral antibiotic therapy for invasive gram-positive infections","volume":"8","author":"Bork","year":"2019","journal-title":"Infect Dis Ther"},{"issue":"2","key":"10.1016\/j.ijantimicag.2020.106210_bib0015","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz028","article-title":"Dalbavancin as secondary therapy for serious Staphylococcus aureus infections in a vulnerable patient population","volume":"6","author":"Bryson-Cahn","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106210_bib0016","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1093\/jac\/dkv344","article-title":"Vascular access complications during outpatient parenteral antimicrobial therapy at home: a retrospective cohort study","volume":"71","author":"Shrestha","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"Supplement_5","key":"10.1016\/j.ijantimicag.2020.106210_bib0017","doi-asserted-by":"crossref","first-page":"S506","DOI":"10.1093\/infdis\/jiaa055","article-title":"Impact of a plan of care protocol on patient outcomes in people who inject drugs with infective endocarditis","volume":"222","author":"Cooksey","year":"2020","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.ijantimicag.2020.106210_bib0018","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1086\/313753","article-title":"Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis","volume":"30","author":"Li","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.ijantimicag.2020.106210_bib0019","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1093\/jac\/dkw326","article-title":"Outpatient use of ceftaroline fosamil versus vancomycin for osteoarticular infection: a matched cohort study","volume":"71","author":"Athans","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.ijantimicag.2020.106210_bib0020","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.diagmicrobio.2016.02.007","article-title":"Reproducibility of dalbavancin MIC test results and an updated surrogate accuracy analysis of vancomycin MIC values to infer dalbavancin susceptibility (2014)","volume":"86","author":"Jones","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"10.1016\/j.ijantimicag.2020.106210_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2017.07.028","article-title":"Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen","volume":"24","author":"Werth","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.ijantimicag.2020.106210_bib0022","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the treatment of osteomyelitis in adult patients: A randomized clinical trial of efficacy and safety","volume":"6","author":"Rappo","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"10.1016\/j.ijantimicag.2020.106210_bib0023","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ijantimicag.2019.08.007","article-title":"Dalbavancin use in an academic medical centre and associated cost savings","volume":"54","author":"Streifel","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"10.1016\/j.ijantimicag.2020.106210_bib0024","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s15010-019-01354-x","article-title":"Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection","volume":"47","author":"Tobudic","year":"2019","journal-title":"Infection"},{"issue":"3","key":"10.1016\/j.ijantimicag.2020.106210_bib0025","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diagmicrobio.2018.10.007","article-title":"Dalbavancin for the management of gram-positive osteomyelitis: Effectiveness and potential utility","volume":"93","author":"Almangour","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"5","key":"10.1016\/j.ijantimicag.2020.106210_bib0026","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/cid\/ciy279","article-title":"Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the general Hospital of Vienna","volume":"67","author":"Tobudic","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.ijantimicag.2020.106210_bib0027","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","article-title":"Dalbavancin in the treatment of different gram-positive infections: a real-life experience","volume":"51","author":"Bouza","year":"2018","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"10.1016\/j.ijantimicag.2020.106210_bib0028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187792","article-title":"Comparative efficacy and safety of antibiotics used to treat acute bacterial skin and skin structure infections: Results of a network meta-analysis","volume":"12","author":"Guest","year":"2017","journal-title":"PLoS One"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920304210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920304210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:41:11Z","timestamp":1760377271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920304210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0924857920304210"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106210","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106210","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106210"}}